Clinical Trials Logo

Clinical Trial Summary

This is a randomized controlled trial with blinded evaluator and follow-up of one year. Seventy six patients with diffuse systemic sclerosis, will be randomized into two groups.The patients can not change their medication during the study. Patients will be evaluated at baseline and at 3, 6, 9 and 12 months. The experimental group will use a serial night time position splint who will be adjusted monthly, while the control group will remain the drug treatment. The outcomes assessed will be: pain, hand range of motion, quality of life, functional capacity, upper limb function and dexterity. Our hypothesis is that the serial night time position splint will improve the hand range of motion in diffuse systemic sclerosis patients.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01586663
Study type Interventional
Source Federal University of São Paulo
Contact Fernanda P Cardoso, OT
Phone 551155764239
Email anamajones@gmail.com
Status Recruiting
Phase Phase 3
Start date January 2010
Completion date December 2012

See also
  Status Clinical Trial Phase
Completed NCT01284322 - Fresolimumab In Systemic Sclerosis Phase 1
Completed NCT01538719 - IL1-TRAP, Rilonacept, in Systemic Sclerosis Phase 1/Phase 2
Terminated NCT04837131 - A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Phase 2